Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

NCT03880279 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Following a change in company governance, Triumvira terminated the study prior to enrolling any subjects due to a challenging competitive landscape.

Conditions

Interventions

Sponsor

Triumvira Immunologics, Inc.